<SEC-DOCUMENT>0001829126-25-002940-index.html : 20250425 <SEC-HEADER>0001829126-25-002940.hdr.sgml : 20250425 <ACCEPTANCE-DATETIME>20250425143800 ACCESSION NUMBER: 0001829126-25-002940 CONFORMED SUBMISSION TYPE: S-1 PUBLIC DOCUMENT COUNT: 7 FILED AS OF DATE: 20250425 DATE AS OF CHANGE: 20250425 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001130166 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 911766850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1 SEC ACT: 1933 Act SEC FILE NUMBER: 333-286754 FILM NUMBER: 25872982 BUSINESS ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 908-517-7330 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 FORMER COMPANY: FORMER CONFORMED NAME: XCYTE THERAPIES INC DATE OF NAME CHANGE: 20001218 </SEC-HEADER> <DOCUMENT> <TYPE>S-1 <SEQUENCE>1 <FILENAME>cyclacel_s1.htm <DESCRIPTION>S-1 <TEXT> Document 1 - file: cyclacel_s1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-5.1 <SEQUENCE>2 <FILENAME>cyclacel_ex5-1.htm <DESCRIPTION>EXHIBIT 5.1 <TEXT> Document 2 - file: cyclacel_ex5-1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-23.1 <SEQUENCE>3 <FILENAME>cyclacel_ex23-1.htm <DESCRIPTION>EXHIBIT 23.1 <TEXT> Document 3 - file: cyclacel_ex23-1.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-FILING FEES <SEQUENCE>4 <FILENAME>cyclacel_ex107.htm <DESCRIPTION>EXHIBIT 107 <TEXT> Document 4 - file: cyclacel_ex107.htm
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>5 <FILENAME>img_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 5 - file: img_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>6 <FILENAME>ex5-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 6 - file: ex5-1_001.jpg
</DOCUMENT> <DOCUMENT> <TYPE>GRAPHIC <SEQUENCE>7 <FILENAME>ex23-1_001.jpg <DESCRIPTION>GRAPHIC <TEXT> Document 7 - file: ex23-1_001.jpg
</DOCUMENT> </SEC-DOCUMENT>